Has Charles Niesen received payments from drug or device companies?

Yes. Drug and device makers reported $6,795 in general payments to Charles Niesen across 341 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Niesen did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Niesen come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Niesen

Pasadena, CANPI 1710915830

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by UCB, Inc. at 31.4% of the total.

$6,795in general payments, 2019–2025

Across 341 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$2K
SK Life Science, Inc.$789
Neurelis, Inc.$783
Corium, LLC$508
Jazz Pharmaceuticals Inc.$430
Acadia Pharmaceuticals Inc$213
plus $2K from 31 others

$1,608in research payments, 2019–2025

Across 4 payments — averaging $402.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$2K

What the payments were for

Food & beverage$6,70399%
Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	96	$2,132
SK Life Science, Inc.	52	$789
Neurelis, Inc.	31	$783
Corium, LLC	32	$508
Jazz Pharmaceuticals Inc.	12	$430
Acadia Pharmaceuticals Inc	8	$213
Aquestive Therapeutics, Inc.	8	$164
Supernus Pharmaceuticals, Inc.	8	$156
Greenwich Biosciences, Inc.	13	$152
Travere Therapeutics, Inc.	24	$151
Takeda Pharmaceuticals U.S.A., Inc.	7	$133
Immedica Pharma US, Inc.	6	$128
Merck	1	$114
Sumitomo Pharma America, Inc.	5	$112
Lilly USA, LLC	5	$108
Mallinckrodt Enterprises LLC	4	$101
Adlon Therapeutics L.p.	4	$63
Eisai Inc.	2	$53
Livanova USA, Inc.	2	$44
Neos Therapeutics, LP	2	$41
AbbVie	1	$34
Xeris Pharmaceuticals, Inc.	2	$34
Biomarin Pharmaceutical Inc.	2	$34
Tris Pharma Inc	1	$28
Mallinckrodt Hospital Products Inc.	1	$27
Intrabio Inc	1	$26
Biogen	1	$25
Neuropace, Inc.	1	$25
Teva Pharmaceuticals USA, Inc.	1	$25
Arbor Pharmaceuticals, Inc.	1	$24
Sarepta Therapeutics, Inc.	1	$23
Argenx US, Inc.	1	$23
Biohaven Pharmaceuticals, Inc.	1	$21
Otsuka America Pharmaceutical, Inc.	1	$20
Azurity Pharmaceuticals, Inc.	1	$20
Collegium Pharmaceutical, Inc.	1	$18
Cranial Technologies, Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ethosuximide	28	$1,391
Gabapentin	27	$178
Quetiapine Fumarate ErQuetiapine Fumarate	12	$176
Sertraline Hcl	39	$149
Lamotrigine	12	$96
Clonidine Hcl	11	$52
Risperidone	12	$40

Paid to pharmacies, not to this prescriber.

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →